Eile korraldas Prilenia veebiseminari, kus ajakohastati III faasi uuringut Pridopidiiniga. Täname kõiki, kes osalesid, ja eriline tänu meie kõnelejatele Michael Haydenile, Andrew Feiginile, Ralf Reilmanile ja Anne Rosserile ning samuti Dina de Sousale Euroopa Huntingtoni Assotsiatsiooni nimel. Jääge kursis, et näha rohkem üritusi mai teadlikkuse kuu jooksul! 
Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the Loe edasi...
Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to Loe edasi...
“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical Loe edasi...
Estonian 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Finnish 
French 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Latvian 
Lithuanian 
Polish 
Portuguese 
Romanian 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian
0 Märkused